# Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

> **NCT04051827** · PHASE1 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 26 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms

## Interventions

- **DRUG:** Midazolam
- **DRUG:** TAK-788

## Key facts

- **NCT ID:** NCT04051827
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-23
- **Primary completion:** 2020-12-17
- **Final completion:** 2021-12-07
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04051827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04051827, "Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04051827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*